JAK2 inhibitors: A reality? A hope?

Clinical lymphoma & myeloma

Volumn 9 Suppl 3, Issue , 2009, Pages

  Apostolidou, Effrosyni ^a   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; JANUS KINASE 2;

BLOOD DISEASE; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PROGNOSIS; REVIEW; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PRIMARY MYELOFIBROSIS; PROGNOSIS; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

MLCS; MLOWN;

EID: 73249131945     PISSN: None     EISSN: 19380712     Source Type: Journal    
DOI: 10.3816/clm.2009.s.033     Document Type: Review

References (68)